Sean Laaman, an analyst from Morgan Stanley, maintained the Buy rating on Disc Medicine. The associated price target remains the same with $90.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Laaman has given his Buy rating due to a combination of factors surrounding Disc Medicine’s innovative treatment approach for Erythropoietic Protoporphyria (EPP). The company’s lead product, bitopertin, is currently under consideration for FDA approval and has shown promising results in clinical trials, particularly in reducing protoporphyrin IX (PPIX) levels and improving the quality of life for patients.
The insights from a leading hepatologist and clinical researcher highlighted the significant clinical benefits of bitopertin, which could potentially address the current treatment gaps in EPP. The expert noted that a substantial portion of his patients would likely opt for bitopertin as a first-line treatment, contingent upon its approval, accessibility, and pricing. This potential for high adoption among patients positions Disc Medicine favorably in the market, supporting the Buy rating.
In another report released on September 30, LifeSci Capital also maintained a Buy rating on the stock with a $85.00 price target.
IRON’s price has also changed dramatically for the past six months – from $45.770 to $67.780, which is a 48.09% increase.